HomeCompareATXMF vs PFE

ATXMF vs PFE: Dividend Comparison 2026

ATXMF yields 71428.57% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATXMF wins by $1.6804617092236922e+25M in total portfolio value
10 years
ATXMF
ATXMF
● Live price
71428.57%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6804617092236922e+25M
Annual income
$16,758,464,082,723,930,000,000,000,000,000.00
Full ATXMF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — ATXMF vs PFE

📍 ATXMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATXMFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATXMF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATXMF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATXMF
Annual income on $10K today (after 15% tax)
$6,071,428.57/yr
After 10yr DRIP, annual income (after tax)
$14,244,694,470,315,339,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, ATXMF beats the other by $14,244,694,470,315,339,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATXMF + PFE for your $10,000?

ATXMF: 50%PFE: 50%
100% PFE50/50100% ATXMF
Portfolio after 10yr
$8.402308546118461e+24M
Annual income
$8,379,232,041,361,964,000,000,000,000,000.00/yr
Blended yield
99.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

ATXMF
No analyst data
Altman Z
-8.4
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATXMF buys
0
PFE buys
0
No recent congressional trades found for ATXMF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATXMFPFE
Forward yield71428.57%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$1.6804617092236922e+25M$49.6K
Annual income after 10y$16,758,464,082,723,930,000,000,000,000,000.00$26,258.71
Total dividends collected$1.6801590475897682e+25M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ATXMF vs PFE ($10,000, DRIP)

YearATXMF PortfolioATXMF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$7,153,557$7,142,857.14$9,153$693.39+$7.14MATXMF
2$4,783,059,608$4,775,405,302.31$8,593$849.25+$4783.05MATXMF
3$2,989,196,089,253$2,984,078,215,471.53$8,336$1,066.78+$2989196.08MATXMF
4$1,746,108,740,720,723$1,742,910,300,905,223.00$8,437$1,384.80+$1746108740.71MATXMF
5$953,366,906,359,837,700$951,498,570,007,266,600.00$9,013$1,875.40+$953366906359.83MATXMF
6$486,546,837,026,708,500,000$485,526,734,436,903,500,000.00$10,306$2,680.72+$486546837026708.50MATXMF
7$232,096,820,383,666,640,000,000$231,576,215,268,048,070,000,000.00$12,820$4,101.38+$232096820383666624.00MATXMF
8$103,489,940,016,498,150,000,000,000$103,241,596,418,687,620,000,000,000.00$17,673$6,826.70+$103489940016498147328.00MATXMF
9$43,133,653,750,454,530,000,000,000,000$43,022,919,514,636,880,000,000,000,000.00$27,543$12,591.86+$4.313365375045453e+22MATXMF
10$16,804,617,092,236,920,000,000,000,000,000$16,758,464,082,723,930,000,000,000,000,000.00$49,560$26,258.71+$1.6804617092236922e+25MATXMF

ATXMF vs PFE: Complete Analysis 2026

ATXMFStock

Advantex Marketing International Inc. operates as an aggregator of independent merchants in Canada. The company operates through Merchant Cash Advance, Program, and Aeroplan Program segments. It also provides merchant cash advance (MCA) and loyalty marketing services to its community of merchants. The MCA meets working capital needs of merchants; and loyalty marketing provides merchants an economic way to market their establishments through its re-seller relationship with Aeroplan loyalty program. In addition, the company provides the Aeroplan program that allows members to earn aeroplan points on purchases at merchants. Further, the company's merchant partners operate in various business segments, including restaurants; independent inns, resorts, and selected hotels; spas; retailers of men's and ladies fashion, footwear, and accessories; florists and garden centers; health and beauty centers; gift stores; and home décor. Advantex Marketing International Inc. was incorporated in 1994 and is headquartered in Toronto, Canada.

Full ATXMF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ATXMF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATXMF vs SCHDATXMF vs JEPIATXMF vs OATXMF vs KOATXMF vs MAINATXMF vs JNJATXMF vs MRKATXMF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.